
  
    
      
        Background_NNP
        Infection_NNP with_IN human_JJ immunodeficiency_NN vims_NNS (_( HIV_NNP )_) elicits_NNS
        an_DT acute_JJ retroviral_NN syndrome_NN characterized_VBN by_IN fever_NN ,_,
        pharyngitis_NNS ,_, lymphadenopathy_NN ,_, myalgia_NN ,_, rash_NN ,_, and_CC headache_NN [_NN
        1_CD ,_, 2_CD ,_, 3_CD ]_NN ._. Sexual_NNP transmission_NN of_IN HIV_NNP infection_NN occurs_VBZ
        mostly_RB via_IN the_DT intestinal_NN or_CC vaginal_JJ mucosa_NN but_CC HIV-I_NNP is_VBZ
        also_RB effectively_RB transmitted_VBN by_IN the_DT intravenous_JJ route_NN [_NN 4_CD ]_NN
        [_NN 5_CD ,_, 6_CD ,_, 7_CD ]_NN ._.
        Recent_JJ studies_NNS have_VBP shown_VBN that_IN the_DT HIV-I_NNP or_CC SIV_NNP virus_NN
        rapidly_RB penetrates_NNS vaginal_JJ ,_, rectal_NN ,_, or_CC oral_JJ mucosa_NN
        attaching_VBG to_TO and_CC infecting_VBG primarily_RB CD_NNP 4_CD +_NN T-_NNP cells_NNS where_WRB it_PRP
        replicates_NNS and_CC consequently_RB spreads_VBZ to_TO lymphoid_NN tissue_NN and_CC
        systemic_JJ organs_NNS [_NN 8_CD ]_NN [_NN 9_CD ,_, 10_CD ,_, 11_CD ,_, 12_CD ]_NN ._.
        Accumulating_NNP evidence_NN has_VBZ implicated_VBN virus-specific_JJ CTL_NNP
        in_IN containing_VBG primary_JJ HIV_NNP /_NN SIV_NNP infection_NN and_CC
        HIV-I_NNP /_NN SIV-specific_NNP CD_NNP 8_CD +_NN CTL_NNP have_VBP been_VBN documented_VBN during_IN the_DT
        early_JJ weeks_NNS following_VBG infection_NN ,_, before_IN a_DT neutralizing_VBG Ab_NNP
        response_NN is_VBZ demonstrable_JJ [_NN 13_CD ]_NN [_NN 14_CD ,_, 15_CD ,_, 16_CD ]_NN ._. Despite_IN the_DT
        rapid_JJ dissemination_NN of_IN HIV-I_NNP by_IN mucosal_NN routes_NNS ,_, productive_JJ
        mucosal_NN transmission_NN appears_VBZ to_TO be_VB relatively_RB inefficient_JJ
        and_CC is_VBZ estimated_VBN to_TO occur_VB once_RB in_IN 300_CD or_CC more_RBR high-risk_JJ
        exposures_NNS [_NN 17_CD ]_NN ._. Cell-mediated_NNP immunity_NN and_CC direct_JJ killing_NN
        by_IN cytotoxic_JJ lymphocytes_NNS from_IN the_DT vagina_NN and_CC colon_NN lamina_NN
        propria_NN may_MD be_VB an_DT important_JJ factor_NN in_IN containing_VBG viral_JJ
        infection_NN at_IN the_DT site_NN of_IN primary_JJ infection_NN [_NN 18_CD ]_NN [_NN 19_CD ,_,
        20_CD ]_NN ._.
        Mucosal_NNP T_NN lymphocytes_NNS appear_VBP to_TO be_VB functionally_RB distinct_JJ
        from_IN those_DT present_NN in_IN the_DT peripheral_JJ circulation_NN ._. While_IN
        activated_VBN T-_NNP cells_NNS reenter_NN lymphoid_NN tissues_NNS and_CC
        preferentially_RB accumulate_VBP at_IN the_DT site_NN of_IN the_DT initial_JJ
        activation_NN ,_, memory_NN T-_NNP cells_NNS migrate_VB continuously_RB and_CC
        randomly_RB ,_, similar_JJ to_TO naive_JJ T-_NNP cells_NNS [_NN 21_CD ]_NN [_NN 22_CD ]_NN ._. The_DT
        implication_NN in_IN terms_NNS of_IN HIV_NNP infection_NN is_VBZ that_IN ,_, in_IN the_DT
        initial_JJ phase_NN of_IN an_DT immune_JJ response_NN ,_, once_RB primed_VBN ,_,
        Ag-specific_NNP memory_NN T-_NNP cells_NNS randomly_RB enter_VBP and_CC leave_VB various_JJ
        lymphoid_NN compartments_NNS but_CC preferentially_RB are_VBP retained_VBN in_IN
        the_DT lymphoid_NN compartment_NN where_WRB the_DT antigen_NN was_VBD presented_VBN at_IN
        first_JJ [_NN 23_CD ]_NN [_NN 24_CD ]_NN ._.
        In_IN humans_NNS ,_, it_PRP is_VBZ unfeasible_JJ to_TO evaluate_VB the_DT
        immunological_JJ events_NNS that_WDT occur_VBP shortly_RB after_IN infection_NN in_IN
        the_DT mucosal_NN compartments_NNS ._. However_RB ,_, in_IN the_DT SIV_NNP 
        mac_NN 251_CD macaque_NN model_NN ,_, some_DT of_IN these_DT
        issues_NNS can_MD be_VB addressed_VBN ._. SIV_NNP 
        mac_NN 251_CD establishes_VBZ persistent_JJ infection_NN
        in_IN rhesus_JJ macaques_NNS and_CC causes_NNS an_DT immunodeficiency_NN syndrome_NN
        closely_RB resembling_VBG human_JJ AIDS_NNP [_NN 25_CD ]_NN [_NN 26_CD ,_, 27_CD ,_, 28_CD ]_NN ._. As_IN in_IN
        humans_NNS ,_, the_DT clinical_JJ course_NN of_IN SIV_NNP 
        mac_NN 251_CD infection_NN varies_VBZ considerably_RB
        among_IN macaques_NNS ._. Recent_JJ evidence_NN from_IN our_PRP$ lab_NN suggests_VBZ that_IN
        macaques_NNS that_WDT express_VBP the_DT major_JJ histocompatibility_NN class_NN I_PRP
        Mamu-_NNP A_DT *_NN 01_CD molecule_NN restrict_VB SIV_NNP 
        mac_NN 251_CD replication_NN following_VBG intrarectal_NN
        exposure_NN ,_, as_IN reported_VBN for_IN HIV-I-infected_NNP individuals_NNS that_WDT
        express_VBP the_DT HLA_NNP B_NNP *_NN 5701_CD [_NN 29_CD ]_NN ,_, further_JJ validating_VBG this_DT
        animal_NN model_NN of_IN HIV-I_NNP infection_NN ._. In_IN this_DT model_NN ,_, virus_NN
        strain_NN ,_, dose_NN ,_, and_CC especially_RB route_NN of_IN infection_NN can_MD be_VB
        defined_VBN and_CC host-virus_JJ interactions_NNS under_IN different_JJ
        conditions_NNS can_MD be_VB assessed_VBN ._. Here_RB we_PRP used_VBD genetically_RB
        defined_VBN Mamu-_NNP A_DT *_NN 01_CD rhesus_JJ macaques_NNS to_TO study_VB the_DT extent_NN of_IN
        virus-specific_JJ CD_NNP 8_CD +_NN T-_NNP cell_NN response_NN and_CC the_DT trafficking_NN of_IN
        lymphocytes_NNS to_TO the_DT gut_NN during_IN the_DT first_JJ 12_CD days_NNS of_IN
        intrarectal_NN or_CC intravenous_JJ transmission_NN of_IN the_DT same_JJ stock_NN
        of_IN SIV_NNP 
        mac_NN 251_CD ._.
      
      
        Materials_NNS
        
          Animals_NNS and_CC procedure_NN
          Two_CD female_JJ Mamu-_NNP A_DT *_NN 01_CD -_: positive_JJ macaques_NNS were_VBD involved_VBN
          in_IN this_DT study_NN :_: animal_NN 817_CD that_WDT was_VBD infected_VBN by_IN undiluted_JJ
          SIV_NNP 
          mac_NN 251_CD /_NN 561_CD stock_NN virus_NN (_( R_NN ._. Pal_NNP 
          et_CC al_NN ._. ,_, unpublished_JJ data_NNS )_) by_IN the_DT
          intrarectal_NN route_NN and_CC animal_NN 819_CD by_IN the_DT intravenous_JJ route_NN
          with_IN a_DT 1_CD :_: 3000_CD dilution_NN of_IN the_DT same_JJ viral_JJ stock_NN ._. Blood_NNP was_VBD
          drawn_VBN before_IN infection_NN and_CC at_IN days_NNS 4_CD ,_, 8_CD ,_, and_CC 12_CD after_IN
          inoculation_NN with_IN the_DT virus_NN ._. Animals_NNS were_VBD sacrificed_JJ at_IN
          day_NN 12_CD postinfection_NN ._. The_DT spleens_NNS and_CC hilar_NN ,_, axillary_JJ ,_,
          mesenteric_JJ ,_, iliac_NN ,_, and_CC inguinal_NN lymph_NN nodes_NNS as_RB well_RB as_IN
          ileums_NNS ,_, jejunums_NNS ,_, and_CC colons_NNS were_VBD collected_VBN in_IN RPMI_NNP
          medium_NN containing_VBG 10_CD %_NN FCS_NNP +_NN penicillin_NN /_NN streptomycin_NN ._.
        
        
          Isolation_NNP of_IN tissue_NN lymphocytes_NNS
          Mononuclear_NNP cells_NNS were_VBD isolated_VBN from_IN peripheral_JJ blood_NN
          (_( PBMC_NNP )_) ,_, lymph_NN nodes_NNS ,_, spleens_NNS ,_, and_CC intestines_NNS ._. Mononuclear_NNP
          cells_NNS from_IN spleens_NNS and_CC lymph_NN nodes_NNS were_VBD isolated_VBN by_IN
          mechanical_JJ dissociation_NN of_IN the_DT tissue_NN and_CC consecutive_JJ
          Ficoll_NNP gradient_NN centrifugation_NN ._. Tissues_NNPS from_IN ileums_NNS ,_,
          jejunums_NNS ,_, and_CC colons_NNS were_VBD treated_VBN with_IN 1_CD mM_NN DTT_NNP (_( ICN_NNP
          Biomedicals_NNP ,_, Aurora_NNP ,_, OH_NNP )_) for_IN 30_CD minutes_NNS followed_VBN by_IN
          incubation_NN in_IN calcium_NN /_NN magnesium-free_JJ HBSS_NNP with_IN EDTA_NNP (_( Life_NNP
          Technologies_NNPS ,_, Baltimore_NNP ,_, MD_NNP )_) 4_CD times_NNS 1_CD hour_NN with_IN stirring_VBG
          at_IN room_NN temperature_NN to_TO remove_VB the_DT epithelial_NN layer_NN ._. At_IN
          this_DT stage_NN ,_, pieces_NNS of_IN tissue_NN were_VBD fixed_VBN in_IN 10_CD %_NN neutral_JJ
          formalin_NN and_CC embedded_VBN in_IN paraffin_NN and_CC sections_NNS were_VBD cut_VBN
          and_CC stained_JJ with_IN H_NNP &_CC E_NNP ._. Microscopic_NNP examination_NN was_VBD
          performed_VBN to_TO ensure_VB that_IN all_DT of_IN the_DT epithelium_NN was_VBD
          removed_VBN and_CC the_DT lamina_NN propria_NN was_VBD intact_JJ ._.
          Further_RB ,_, tissues_NNS were_VBD cut_VBN into_IN smaller_JJR pieces_NNS and_CC
          incubated_JJ at_IN 37_CD °_NN C_NNP in_IN Isocove_NNP 's_POS medium_NN supplemented_JJ with_IN
          10_CD %_NN fetal_JJ calf_NN serum_NN and_CC penicillin_NN /_NN streptomycin_NN
          containing_VBG 400_CD U_NNP /_NN ml_NN Collagenase_NNP D_NNP (_( Boerrhinghem_NNP &_CC
          Mannheim_NNP GmbH_NNP ,_, Mannheim_NNP ,_, Germany_NNP )_) and_CC 25_CD U_NNP /_NN ml_NN DNAse_NNP
          (_( Worthington_NNP Biochemical_NNP ,_, Lakewood_NNP ,_, NJ_NNP )_) for_IN 2_CD -_: 3_CD hours_NNS ._.
          The_DT mononuclear_NN cells_NNS were_VBD isolated_VBN from_IN the_DT supernatant_NN
          containing_VBG dissociated_JJ cells_NNS by_IN Percoll_NNP gradient_NN
          centrifugation_NN ._.
        
        
          Flow_NNP cytometry_NN
          Fresh_NNP mononuclear_NN cells_NNS were_VBD directly_RB stained_JJ with_IN
          PE-conjugated_NNP tetrameric_JJ complexes_NNS for_IN Gag_NNP 181_CD ,_, Env_NNP 622_CD ,_,
          and_CC Tat_NNP 28_CD ._. PerCP-conjugated_NNP anti-_NN CD_NNP 3_CD e_SYM (_( Pharmingen_NNP ,_, San_NNP
          Diego_NNP ,_, CA_NNP )_) and_CC FITC-conjugated_NNP anti-_NN CD_NNP 8_CD (_( Becton_NNP
          Dickinson_NNP ,_, San_NNP Jose_NNP ,_, CA_NNP )_) were_VBD used_VBN in_IN conjunction_NN with_IN
          the_DT tetrameric_JJ complexes_NNS ._. In_IN addition_NN ,_, cells_NNS were_VBD stained_JJ
          with_IN a_DT combination_NN of_IN anti-_NN CD_NNP 3_CD PerCP_NNP ,_, anti-_NN CD_NNP 8_CD FITC_NNP and_CC
          anti_NN CD_NNP 4_CD PE_NNP (_( Becton_NNP Dickinson_NNP ,_, San_NNP Jose_NNP ,_, CA_NNP )_) ._. To_TO assess_VB
          their_PRP$ proliferative_JJ ability_NN and_CC to_TO confirm_VB the_DT
          specificity_NN of_IN tetramer_NN staining_VBG of_IN 
          ex_FW vivo_NN CD_NNP 3_CD +_NN CD_NNP 8_CD +_NN T-_NNP cells_NNS ,_,
          lymphocytes_NNS were_VBD cultured_JJ at_IN a_DT concentration_NN of_IN 3_CD ×_NN 10_CD
          6_CD /_NN ml_NN in_IN RPMI_NNP enriched_JJ with_IN 10_CD %_NN human_JJ serum_NN with_IN addition_NN
          of_IN 10_CD μg_NN /_NN ml_NN of_IN the_DT appropriate_JJ peptide_NN and_CC 20_CD U_NNP /_NN ml_NN of_IN
          IL-_NNP 2_CD for_IN 7_CD days_NNS ._. Staining_NNP with_IN tetrameric_JJ complexes_NNS was_VBD
          done_VBN afterward_RB as_IN described_VBN above_IN ._.
          Briefly_NNP ,_, 5_CD ×_NN l_NN 0_CD 5_CD lymphocytes_NNS isolated_VBN by_IN Ficoll_NNP
          diatrizoate_NN or_CC Percoll_NNP gradient_NN centrifugation_NN were_VBD
          incubated_JJ with_IN tetrameric_JJ complexes_NNS as_RB previously_RB
          described_VBD [_NN 30_CD ]_NN and_CC /_NN or_CC selected_VBN Ab_NNP for_IN 30_CD minutes_NNS at_IN room_NN
          temperature_NN ._. After_IN washing_VBG the_DT cells_NNS twice_RB in_IN Dulbecco_NNP 's_POS
          phosphate_NN buffered_JJ saline_NN supplemented_JJ with_IN 2_CD %_NN FCS_NNP and_CC
          fixation_NN in_IN 1_CD %_NN paraformaldehyde_NN (_( Ph_NNP =_SYM 7_CD ._. 4_LS )_) ,_, samples_NNS were_VBD
          analyzed_VBN by_IN flow_NN cytometry_NN using_VBG FACScalibur_NNP (_( Becton_NNP
          Dickinson_NNP ,_, San_NNP Jose_NNP ,_, CA_NNP )_) instrument_NN ._.
        
        
          Viral_NNP load_NN (_( NASBA_NNP )_)
          SIV_NNP 
          mac_NN 251_CD viral_JJ RNA_NNP copies_NNS in_IN plasma_NN was_VBD
          quantified_VBN by_IN nucleic-acid-sequence-based_JJ amplification_NN [_NN
          31_CD ]_NN ._. Briefly_NNP ,_, RNA_NNP extracted_VBD from_IN plasma_NN was_VBD subjected_VBN to_TO
          isothermal_NN amplification_NN with_IN SIV_NNP 
          mac_NN 251_CD -_: specific_JJ primers_NNS ._. A_DT portion_NN of_IN
          the_DT SIV_NNP wild_JJ type_NN Gag_NNP gene_NN was_VBD used_VBN to_TO generate_VB internal_JJ
          control_NN ._. NASBA_NNP amplification_NN products_NNS were_VBD detected_VBN by_IN
          using_VBG chemiluminescence-based_JJ probe_NN hybridization_NN system_NN ._.
          The_DT assay_NN can_MD measure_VB accurately_RB tenfold_RB changes_VBZ and_CC is_VBZ
          functional_JJ over_IN a_DT dynamic_JJ range_NN spanning_VBG at_IN least_JJS 10_CD 4_CD -_: 10_CD
          7_CD copies_NNS ._.
        
      
      
        Results_NNS
        
          Kinetics_NNP of_IN viral_JJ appearance_NN and_CC CD_NNP 4_CD +_NN T-_NNP cell_NN
          decrease_NN in_IN the_DT blood_NN
          Since_IN the_DT knowledge_NN of_IN the_DT Mamu-_NNP A_DT *_NN 01_CD -_: restricted_VBN
          epitopes_NNS [_NN 32_CD ]_NN [_NN 33_CD ]_NN allows_VBZ for_IN a_DT quantitation_NN of_IN the_DT CD_NNP 8_CD +_NN
          T-_NNP cell_NN response_NN using_VBG the_DT tetramer_NN technology_NN [_NN 34_CD ]_NN ,_,
          Mamu-_NNP A_DT *_NN 01_CD macaques_NNS were_VBD chosen_VBN for_IN this_DT study_NN ._. Following_VBG
          exposure_NN to_TO the_DT same_JJ viral_JJ stock_NN of_IN SIV_NNP 
          mac_NN 251_CD of_IN macaque_NN 817_CD by_IN the_DT
          intrarectal_NN route_NN and_CC macaque_NN 819_CD by_IN the_DT intravenous_JJ
          route_NN ,_, the_DT kinetics_NNS of_IN viral_JJ RNA_NNP appearance_NN in_IN the_DT plasma_NN
          was_VBD assessed_VBN by_IN NASBA_NNP ._. Plasma_NNP viral_JJ RNA_NNP was_VBD detected_VBN as_RB
          early_RB as_IN day_NN 8_CD in_IN animal_NN 819_CD ,_, exposed_VBN by_IN the_DT intravenous_JJ
          route_NN ,_, and_CC was_VBD highest_JJS at_IN time_NN of_IN euthanasia_NN (_( day_NN 12_CD )_) ,_, as_IN
          demonstrated_VBN in_IN Fig_NNP ._. 1_LS C_NNP ._. In_IN contrast_NN ,_, in_IN animal_NN 817_CD ,_,
          exposed_VBN by_IN the_DT intrarectal_NN route_NN ,_, the_DT appearance_NN of_IN
          plasma_NN virus_NN was_VBD delayed_VBN to_TO day_NN 12_CD postinfection_NN (_( Fig_NNP ._.
          1_LS A_DT )_) and_CC at_IN that_DT time_NN plasma_NN viral_JJ RNA_NNP was_VBD 2_CD logs_NNS lower_JJR in_IN
          animal_NN 817_CD than_IN in_IN animal_NN 819_CD (_( Figs_NNP ._. 1_LS Aand_NNP 1_CD C_NNP )_) ._. The_DT
          absolute_JJ number_NN of_IN CD_NNP 4_CD +_NN T-_NNP cells_NNS /_NN mm_NN 3_CD blood_NN decreased_VBN by_IN
          50_CD %_NN in_IN both_DT macaques_NNS by_IN day_NN 12_CD (_( Figs_NNP ._. 1_LS Aand_NNP 1_CD C_NNP )_) ._. However_RB ,_,
          the_DT absolute_JJ number_NN of_IN CD_NNP 8_CD +_NN T-_NNP cells_NNS and_CC CD_NNP 3_CD +_NN T-_NNP cells_NNS
          decreased_VBD as_IN well_RB ,_, indicating_VBG that_IN the_DT apparent_JJ depletion_NN
          of_IN CD_NNP 4_CD +_NN T-_NNP cells_NNS may_MD be_VB due_JJ to_TO redistribution_NN rather_RB than_IN
          loss_NN of_IN CD_NNP 4_CD +_NN T-_NNP cells_NNS at_IN this_DT stage_NN of_IN infection_NN ._.
          Since_IN animal_NN 817_CD received_VBD three_CD thousandfold_NN more_JJR
          virus_NN than_IN animal_NN 819_CD ,_, these_DT data_NNS suggest_VBP that_IN the_DT
          kinetics_NNS of_IN viral_JJ appearance_NN in_IN the_DT blood_NN in_IN primary_JJ SIV_NNP 
          mac_NN 251_CD infection_NN may_MD depend_VB on_IN the_DT
          route_NN of_IN challenge_NN rather_RB than_IN dose_NN ._.
        
        
          Virus-specific_NNP CD_NNP 8_CD +_NN T-_NNP cell_NN response_NN in_IN the_DT
          blood_NN
          Virus-specific_NNP CD_NNP 8_CD +_NN T-_NNP cells_NNS were_VBD quantitated_JJ in_IN the_DT
          blood_NN of_IN both_DT animals_NNS at_IN days_NNS 0_CD ,_, 4_CD ,_, and_CC 12_CD postinfection_NN
          using_VBG 3_CD tetrameric_JJ Mamu-_NNP A_DT *_NN 01_CD molecules_NNS complexed_JJ with_IN the_DT
          SIV_NNP 
          mac_NN Gag_NNP 181_CD ,_, Env_NNP 622_CD ,_, and_CC Tat_NNP 28_CD
          peptides_NNS (_( T_NN ._. M_NNP ._. Alien_NNP 
          et_CC al_NN ._. ,_, submitted_VBN )_) ._.
          In_IN the_DT blood_NN ,_, virus-specific_JJ tetramer-binding_JJ CD_NNP 3_CD +_NN
          CD_NNP 8_CD +_NN T-_NNP cells_NNS appeared_VBD earlier_RBR in_IN macaque_NN 817_CD ,_, exposed_VBN to_TO
          SIV_NNP 
          mac_NN 251_CD by_IN the_DT intrarectal_NN route_NN ,_, than_IN
          in_IN 819_CD for_IN all_PDT the_DT 3_CD antigens_NNS studied_VBN (_( Figs_NNP ._. 1_LS Band_NNP 1_CD D_NNP )_) ._.
          Overall_RB ,_, the_DT size_NN of_IN the_DT virus-specific_JJ CD_NNP 8_CD +_NN T-_NNP cell_NN
          response_NN in_IN the_DT blood_NN was_VBD higher_JJR in_IN animal_NN 817_CD and_CC ,_,
          interestingly_RB ,_, a_DT large_JJ population_NN of_IN Tat-specific_NNP CD_NNP 8_CD +_NN
          T-_NNP cells_NNS appeared_VBD in_IN the_DT blood_NN as_RB early_RB as_IN day_NN 4_CD ,_, whereas_IN
          in_IN the_DT same_JJ animal_NN CD_NNP 8_CD +_NN T-_NNP cells_NNS specific_JJ to_TO Gag_NNP 181_CD and_CC
          Env_NNP 622_CD peaked_VBD later_RB (_( Fig_NNP ._. 1_LS )_) ._. These_DT data_NNS are_VBP consistent_JJ
          with_IN previous_JJ observations_NNS on_IN the_DT kinetics_NNS of_IN appearance_NN
          of_IN virus-specific_JJ CD_NNP 8_CD +_NN T-_NNP cells_NNS that_WDT recognize_VBP the_DT Tat_NNP 28_CD
          epitope_NN and_CC underscore_VBP the_DT importance_NN of_IN the_DT immune_JJ
          response_NN to_TO this_DT early_JJ SIV_NNP 
          mac_NN 251_CD protein_NN [_NN 35_CD ]_NN [_NN 36_CD ,_, 37_CD ]_NN ._.
        
        
          Absence_NNP of_IN CD_NNP 4_CD +_NN T-_NNP cell_NN depletion_NN in_IN the_DT GALT_NNP of_IN
          Mamu-_NNP A_DT *_NN 01_CD macaques_NNS
          Both_DT macaques_NNS were_VBD euthanized_JJ at_IN day_NN 12_CD and_CC the_DT
          relative_JJ percentages_NNS of_IN CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T-_NNP cells_NNS was_VBD
          assessed_VBN in_IN various_JJ compartments_NNS ._. In_IN contrast_NN to_TO previous_JJ
          reports_NNS [_NN 38_CD ]_NN [_NN 39_CD ]_NN ,_, depletion_NN of_IN CD_NNP 4_CD +_NN T-_NNP cells_NNS was_VBD not_RB
          observed_VBN in_IN any_DT tissues_NNS ,_, including_VBG the_DT GALT_NNP of_IN either_DT
          animal_NN (_( Fig_NNP ._. 2_LS )_) ._. It_PRP is_VBZ possible_JJ that_IN both_DT animals_NNS could_MD
          have_VB controlled_VBN viral_JJ replication_NN or_CC that_IN the_DT tissues_NNS
          were_VBD examined_VBN too_RB early_JJ and_CC that_DT depletion_NN would_MD have_VB
          occurred_VBN at_IN a_DT latter_JJ stage_NN of_IN the_DT infection_NN ._. Preservation_NNP
          of_IN CD_NNP 4_CD +_NN T-_NNP cell_NN depletion_NN in_IN the_DT GALT_NNP during_IN primary_JJ
          infection_NN may_MD be_VB a_DT key_JJ event_NN in_IN delaying_VBG disease_NN
          progression_NN ._.
        
        
          Quantitation_NNP of_IN ex_FW vivoCD_NN 8_CD +_NN T-_NNP cell_NN response_NN in_IN
          tissues_NNS
          Virus-specific_NNP Gag_NNP 181_CD CD_NNP 8_CD +_NN T-_NNP cell_NN response_NN in_IN the_DT
          blood_NN of_IN macaques_NNS exposed_VBN intravenously_RB to_TO SIV_NNP 
          mac_NN 251_CD appears_VBZ to_TO peak_VB within_IN the_DT
          first_JJ weeks_NNS following_VBG intravenous_JJ exposure_NN [_NN 40_CD ]_NN ._.
          Therefore_RB ,_, both_DT macaques_NNS were_VBD euthanized_JJ at_IN day_NN 12_CD and_CC
          lymphocytes_NNS were_VBD harvested_VBN from_IN several_JJ systemic_JJ tissues_NNS
          as_RB well_RB as_IN the_DT GALT_NNP ._. Quantitation_NNP of_IN the_DT 
          ex_FW vivo_NN CD_NNP 8_CD +_NN T-_NNP cell_NN population_NN
          specific_JJ for_IN Gag_NNP ,_, Tat_NNP ,_, and_CC Env_NNP in_IN the_DT systemic_JJ tissues_NNS of_IN
          both_DT animals_NNS revealed_VBD that_IN ,_, in_IN contrast_NN to_TO the_DT blood_NN ,_, the_DT
          highest_JJS virus-specific_JJ CD_NNP 8_CD +_NN T-_NNP cell_NN response_NN was_VBD found_VBN in_IN
          most_JJS tissues_NNS of_IN animal_NN 819_CD ,_, challenged_VBN by_IN the_DT intravenous_JJ
          route_NN (_( Figs_NNP ._. 3_LS and_CC 4_CD and_CC Table_NNP )_) ._. In_IN the_DT same_JJ animal_NN ,_, the_DT
          percentage_NN of_IN CD_NNP 8_CD +_NN T-_NNP cells_NNS specific_JJ for_IN Tat_NNP 28_CD was_VBD as_RB
          high_JJ as_IN 8_CD %_NN ,_, 6_CD %_NN ,_, and_CC 4_CD %_NN in_IN the_DT axillary_JJ and_CC iliac_NN lymph_NN
          nodes_NNS and_CC the_DT spleen_NN ,_, respectively_RB (_( Fig_NNP ._. 3_LS Aand_NNP Table_NNP )_) ._.
          The_DT number_NN of_IN CD_NNP 8_CD +_NN T-_NNP cells_NNS with_IN different_JJ specificities_NNS
          was_VBD also_RB higher_JJR in_IN animal_NN 819_CD than_IN 817_CD in_IN the_DT GALT_NNP and_CC
          particularly_RB in_IN the_DT jejunum_NN and_CC ileum_NN lamina_NN propria_NN
          (_( Figs_NNP ._. 4_LS A_DT ,_, 4_CD B_NNP ,_, 4_CD C_NNP )_) while_IN the_DT size_NN of_IN these_DT virus-specific_JJ
          responses_NNS in_IN the_DT remaining_VBG tissues_NNS of_IN both_DT animals_NNS did_VBD
          not_RB differ_VB significantly_RB (_( Table_NNP )_) ._. These_DT data_NNS indicate_VBP
          that_IN both_DT the_DT Gag_NNP 181_CD and_CC Tat_NNP 28_CD responses_NNS are_VBP codominant_NN
          and_CC suggest_VBP that_IN the_DT overall_JJ higher_JJR CD_NNP 8_CD +_NN T-_NNP cell_NN response_NN
          in_IN animal_NN 819_CD may_MD be_VB related_VBN to_TO an_DT ongoing_JJ higher_JJR viral_JJ
          replication_NN in_IN the_DT tissues_NNS of_IN this_DT animal_NN ,_, as_IN reflected_VBN
          by_IN the_DT higher_JJR level_NN of_IN plasma_NN viremia_NN present_JJ at_IN the_DT time_NN
          of_IN euthanasia_NN ._.
        
        
          Differential_NNP proliferative_JJ ability_NN of_IN
          tetramer-binding_JJ CD_NNP 8_CD +_NN cells_NNS in_IN tissues_NNS of_IN animals_NNS 817_CD and_CC
          819_CD
          Blood_NNP ,_, lymph_NN nodes_NNS ,_, and_CC lamina_NN propria_NN lymphocytes_NNS
          were_VBD cultured_JJ 
          in_IN vitro_NN in_IN the_DT presence_NN of_IN IL-_NNP 2_CD
          and_CC the_DT virus-specific_JJ Gag_NNP 181_CD ,_, Tat_NNP 28_CD ,_, and_CC Env_NNP 622_CD
          peptides_NNS to_TO assess_VB the_DT ability_NN of_IN the_DT tetramer-positive_JJ
          CD_NNP 8_CD +_NN T-_NNP cell_NN population_NN to_TO expand_VB upon_IN antigen_NN
          stimulation_NN ._. In_IN our_PRP$ experimental_JJ conditions_NNS ,_, expansion_NN of_IN
          CD_NNP 8_CD +_NN T-_NNP cells_NNS specific_JJ for_IN Tat_NNP ,_, Env_NNP ,_, and_CC Gag_NNP occurred_VBD to_TO a_DT
          comparable_JJ extent_NN in_IN most_JJS tissues_NNS and_CC was_VBD highest_JJS in_IN the_DT
          blood_NN of_IN animal_NN 819_CD (_( Fig_NNP ._. 5_LS B_NNP )_) ._. In_IN animal_NN 817_CD ,_, the_DT ability_NN
          of_IN virus-specific_JJ CD_NNP 8_CD +_NN T-_NNP cells_NNS to_TO proliferate_VBP was_VBD highest_JJS
          in_IN the_DT jejunum_NN and_CC was_VBD higher_JJR than_IN that_DT observed_VBD in_IN the_DT
          same_JJ compartment_NN in_IN animal_NN 819_CD (_( Fig_NNP ._. 5_LS A_DT )_) ._. The_DT finding_VBG
          that_IN the_DT highest_JJS level_NN of_IN CD_NNP 8_CD +_NN T-_NNP cells_NNS with_IN proliferative_JJ
          ability_NN was_VBD in_IN the_DT lamina_NN propria_NN of_IN the_DT jejunum_NN of_IN
          animal_NN 817_CD challenged_VBN intrarectally_RB is_VBZ suggestive_JJ of_IN a_DT
          qualitative_JJ difference_NN of_IN CD_NNP 8_CD +_NN T-_NNP cells_NNS present_JJ at_IN the_DT
          site_NN of_IN induction_NN and_CC of_IN heterogeneity_NN in_IN the_DT
          virus-specific_JJ CD_NNP 8_CD +_NN response_NN ._.
        
      
      
        Discussion_NNP
        The_DT impact_NN that_IN the_DT route_NN of_IN viral_JJ entry_NN of_IN HIV_NNP /_NN SIV_NNP may_MD
        have_VB on_IN the_DT virus-specific_JJ immune_JJ response_NN and_CC control_NN of_IN
        viral_JJ replication_NN to_TO it_PRP is_VBZ not_RB yet_RB fully_RB understood_VBN ._. Here_RB
        we_PRP conducted_VBD a_DT small_JJ pilot_NN study_NN using_VBG genetically_RB defined_VBN
        Mamu-_NNP A_DT *_NN 01_CD macaques_NNS to_TO study_VB the_DT vims-specific_JJ immune_JJ
        response_NN following_VBG parenteral_NN or_CC rectal_NN exposure_NN to_TO SIV_NNP 
        mac_NN 251_CD This_DT study_NN was_VBD designed_VBN to_TO begin_VB
        to_TO investigate_VB the_DT specificity_NN of_IN the_DT immune_JJ response_NN and_CC
        its_PRP$ kinetics_NNS as_RB well_RB as_IN the_DT kinetics_NNS of_IN viral_JJ replication_NN
        according_VBG to_TO the_DT site_NN of_IN primary_JJ exposure_NN and_CC viral_JJ
        entry_NN ._.
        Within_IN the_DT limitation_NN of_IN the_DT small_JJ number_NN of_IN animals_NNS
        used_VBN here_RB ,_, the_DT mucosal_NN barrier_NN delayed_VBD the_DT appearance_NN of_IN
        virus_NN in_IN the_DT plasma_NN whereas_IN the_DT decrease_NN in_IN the_DT absolute_JJ
        CD_NNP 4_CD +_NN T-_NNP cell_NN counts_VBZ was_VBD equivalent_NN ._. In_IN addition_NN ,_, in_IN contrast_NN
        to_TO other_JJ reports_NNS [_NN 41_CD ]_NN [_NN 38_CD ]_NN ,_, depletion_NN of_IN CD_NNP 4_CD +_NN T-_NNP cells_NNS in_IN
        the_DT GALT_NNP at_IN day_NN 12_CD postinfection_NN was_VBD not_RB observed_VBN in_IN either_DT
        animal_NN regardless_RB of_IN the_DT route_NN of_IN challenge_NN ._. It_PRP is_VBZ unclear_JJ
        what_WP is_VBZ the_DT reason_NN for_IN this_DT finding_VBG ._. It_PRP is_VBZ possible_JJ that_IN
        both_DT animals_NNS could_MD have_VB controlled_VBN the_DT infection_NN or_CC that_IN
        the_DT tissues_NNS were_VBD examined_VBN too_RB early_JJ and_CC that_DT depletion_NN
        would_MD have_VB occurred_VBN at_IN a_DT latter_JJ stage_NN of_IN the_DT infection_NN ._.
        The_DT finding_NN of_IN a_DT higher_JJR percentage_NN of_IN tetramer-positive_JJ
        CD_NNP 8_CD +_NN T-_NNP cells_NNS in_IN tissues_NNS of_IN macaque_NN 819_CD ,_, infected_JJ
        intravenously_RB ,_, than_IN in_IN animal_NN 817_CD ,_, infected_JJ intrarectally_RB ,_,
        may_MD reflect_VB a_DT higher_JJR rate_NN of_IN viral_JJ replication_NN in_IN tissues_NNS
        of_IN this_DT animal_NN at_IN the_DT time_NN of_IN sacrifice_NN ._. Of_IN interest_NN ,_, the_DT
        intrarectal_NN route_NN of_IN infection_NN resulted_VBD in_IN faster_JJR kinetics_NNS
        of_IN appearance_NN of_IN virus-specific_JJ CD_NNP 8_CD +_NN T-_NNP cells_NNS ,_, particularly_RB
        in_IN the_DT Tat_NNP epitope_NN in_IN the_DT blood_NN ,_, indicating_VBG the_DT importance_NN
        of_IN this_DT immune_JJ response_NN early_RB in_IN infection_NN ._. In_IN the_DT same_JJ
        animal_NN ,_, a_DT higher_JJR number_NN of_IN tetramer-specific_JJ CD_NNP 8_CD +_NN T-_NNP cells_NNS
        able_JJ to_TO proliferate_VBP in_IN response_NN to_TO all_DT epitopes_NNS tested_VBN (_( Gag_NNP
        181_CD ,_, Tat_NNP 28_CD ,_, and_CC Env_NNP 622_CD )_) was_VBD found_VBN in_IN jejunum_NN lamina_NN
        propria_NN than_IN in_IN other_JJ tissues_NNS ._. Unfortunately_RB ,_, at_IN present_JJ ,_,
        it_PRP is_VBZ not_RB possible_JJ to_TO assess_VB whether_IN the_DT differences_NNS in_IN the_DT
        proliferative_JJ ability_NN of_IN these_DT cells_NNS reflect_VBP functional_JJ
        status_NN and_CC /_NN or_CC differentiation_NN differences_NNS (_( effector_NN versus_CC
        memory_NN )_) or_CC others_NNS ,_, in_IN part_NN because_IN markers_NNS to_TO define_VB
        accurately_RB these_DT cells_NNS in_IN rhesus_JJ macaques_NNS are_VBP not_RB
        available_JJ ._.
      
      
        Conclusions_NNP
        In_IN conclusion_NN ,_, this_DT study_NN ,_, within_IN the_DT limitation_NN of_IN the_DT
        small_JJ number_NN of_IN animals_NNS used_VBN ,_, appears_VBZ to_TO suggest_VB that_DT
        exposure_NN by_IN the_DT mucosal_NN site_NN ,_, a_DT natural_JJ barrier_NN to_TO
        pathogens_NNS ,_, delays_NNS viral_JJ appearance_NN in_IN the_DT blood_NN ._. The_DT
        differences_NNS in_IN the_DT relative_JJ percentage_NN of_IN homing_VBG markers_NNS
        may_MD not_RB necessarily_RB reflect_VB a_DT true_JJ qualitative_JJ difference_NN
        in_IN the_DT overall_JJ lymphocyte_NN trafficking_NN related_VBN to_TO the_DT mode_NN
        of_IN viral_JJ encounter_NN and_CC may_MD depend_VB on_IN the_DT time_NN of_IN analysis_NN ,_,
        since_IN the_DT kinetic_JJ of_IN viral_JJ replication_NN was_VBD delayed_VBN in_IN the_DT
        macaque_NN exposed_VBN intrarectally_RB ._. Nevertheless_RB ,_, these_DT data_NNS
        demonstrate_VBP that_IN a_DT short_JJ window_NN of_IN opportunity_NN to_TO contain_VB
        viral_JJ infection_NN following_VBG mucosal_NN exposure_NN exists_VBZ and_CC that_IN
        potentiating_VBG the_DT effectiveness_NN of_IN the_DT mucosal_NN natural_JJ
        barrier_NN by_IN local_JJ immunization_NN may_MD further_VB limit_VB or_CC halt_VB
        viral_JJ replication_NN ._. In_IN fact_NN ,_, in_IN a_DT previous_JJ study_NN ,_, we_PRP have_VBP
        observed_VBN that_IN it_PRP appears_VBZ to_TO be_VB easier_JJR to_TO protect_VB vaccinated_JJ
        macaques_NNS by_IN intrarectal_NN exposure_NN than_IN intravenous_JJ exposure_NN
        to_TO SIV_NNP 
        251_CD [_NN 42_CD ]_NN ._. In_IN particular_JJ ,_, since_IN a_DT CD_NNP 8_CD +_NN
        T-_NNP cell_NN response_NN to_TO Tat_NNP appears_VBZ to_TO be_VB the_DT earliest_JJS ,_, this_DT
        protein_NN may_MD be_VB a_DT key_JJ component_NN of_IN a_DT preventive_JJ vaccine_NN ,_, as_IN
        suggested_VBN by_IN other_JJ [_NN 35_CD ]_NN [_NN 36_CD ,_, 37_CD ,_, 43_CD ]_NN ._.
      
      
        List_NN of_IN abbreviations_NNS
        HIV_NNP (_( human_JJ immunodeficiency_NN virus_NN )_)
        HEV_NNP (_( high_JJ endothelial_NN venules_NNS )_)
        PBMC_NNP (_( peripheral_JJ blood_NN mononuclear_NN cells_NNS )_)
      
      
        Declaration_NNP of_IN Competing_VBG Interests_NNP
        Competing_VBG interests_NNS :_: none_NN declared_VBD ._.
      
    
  
